AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CI
  4. [8-K] The Cigna Group Reports Material Event

[8-K] The Cigna Group Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

The Cigna Group filed an 8-K reporting the filing of transaction-related exhibits dated September 2 and September 4, 2025. The company attached an Underwriting Agreement dated September 2, 2025 between The Cigna Group and BofA Securities, Citigroup, HSBC Securities (USA) and Morgan Stanley as representatives of the underwriters. It also included Supplemental Indenture No. 8 dated September 4, 2025 with U.S. Bank Trust Company, National Association as trustee, a legal opinion of Davis Polk & Wardwell LLP, and that firm鈥檚 consent. The filing identifies the company鈥檚 principal executive office in Bloomfield, Connecticut and trading symbol CI on the NYSE.

The Cigna Group ha depositato un modulo 8-K riportando l'inclusione di allegati relativi alla transazione datati 2 e 4 settembre 2025. La societ脿 ha allegato un Underwriting Agreement del 2 settembre 2025 tra The Cigna Group e BofA Securities, Citigroup, HSBC Securities (USA) e Morgan Stanley in qualit脿 di rappresentanti degli offerenti. 脠 stato incluso anche il Supplemental Indenture n. 8 datato 4 settembre 2025 con U.S. Bank Trust Company, National Association come trustee, un parere legale di Davis Polk & Wardwell LLP e il relativo consenso dello studio. Nel documento 猫 indicata la sede principale della societ脿 a Bloomfield, Connecticut e il simbolo di negoziazione CI alla NYSE.

The Cigna Group present贸 un formulario 8-K informando sobre la incorporaci贸n de anexos relacionados con la transacci贸n fechados el 2 y el 4 de septiembre de 2025. La compa帽铆a adjunt贸 un Underwriting Agreement con fecha 2 de septiembre de 2025 entre The Cigna Group y BofA Securities, Citigroup, HSBC Securities (USA) y Morgan Stanley como representantes de los suscriptores. Tambi茅n incluy贸 el Supplemental Indenture n.潞 8 fechado el 4 de septiembre de 2025 con U.S. Bank Trust Company, National Association como fideicomisario, un dictamen legal de Davis Polk & Wardwell LLP y el consentimiento de dicha firma. La presentaci贸n se帽ala la oficina ejecutiva principal en Bloomfield, Connecticut y el s铆mbolo de cotizaci贸n CI en la NYSE.

The Cigna Group電� 2025雲� 9鞗� 2鞚� 氚� 9鞗� 4鞚检瀽 瓯半灅 甏�霠� 靹滊鞚� 鞝滌稖鞚� 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 2025雲� 9鞗� 2鞚检瀽 Underwriting Agreement毳� The Cigna Group瓿� 鞚胳垬鞚� 雽�響滊靹� BofA Securities, Citigroup, HSBC Securities (USA), Morgan Stanley 臧勳棎 觳秬頄堨姷雼堧嫟. 霕愴暅 2025雲� 9鞗� 4鞚检瀽 Supplemental Indenture No. 8毳� 靾橅儊鞛愳澑 U.S. Bank Trust Company, National Association瓿� 頃粯 韽暔頄堨溂氅�, Davis Polk & Wardwell LLP鞚� 氩曥爜 鞚橁铂靹滌檧 攴� 須岇偓鞚� 霃欖潣靹滊弰 觳秬霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 氤胳偓鞚� 靻岇灛歆�臧� 旖旊劋韹办环欤� 敫旊８頃勲摐鞚措┌ NYSE 瓯半灅 鞁臣鞚� CI搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

The Cigna Group a d茅pos茅 un formulaire 8-K signalant l'ajout de pi猫ces li茅es 脿 la transaction dat茅es des 2 et 4 septembre 2025. La soci茅t茅 a joint un Underwriting Agreement dat茅 du 2 septembre 2025 entre The Cigna Group et BofA Securities, Citigroup, HSBC Securities (USA) et Morgan Stanley en tant que repr茅sentants des souscripteurs. Elle a 茅galement inclus le Supplemental Indenture n掳 8 dat茅 du 4 septembre 2025 avec U.S. Bank Trust Company, National Association en qualit茅 de fiduciaire, un avis juridique de Davis Polk & Wardwell LLP ainsi que le consentement de ce cabinet. Le d茅p么t indique le si猫ge social 脿 Bloomfield, Connecticut et le symbole de cotation CI 脿 la NYSE.

The Cigna Group reichte ein Formular 8-K ein und berichtete 眉ber die Einreichung transaktionsbezogener Anlagen vom 2. und 4. September 2025. Das Unternehmen f眉gte ein Underwriting Agreement vom 2. September 2025 zwischen The Cigna Group und BofA Securities, Citigroup, HSBC Securities (USA) und Morgan Stanley als Vertreter der Zeichner bei. Ebenfalls beigef眉gt ist das Supplemental Indenture Nr. 8 vom 4. September 2025 mit der U.S. Bank Trust Company, National Association als Treuh盲nder, ein rechtliches Gutachten von Davis Polk & Wardwell LLP sowie die Zustimmung dieser Kanzlei. In der Einreichung wird der Hauptsitz in Bloomfield, Connecticut und das B枚rsensymbol CI an der NYSE angegeben.

Positive
  • Underwriting Agreement dated September 2, 2025 was filed with named lead underwriters (BofA, Citigroup, HSBC Securities (USA), Morgan Stanley)
  • Supplemental Indenture No. 8 dated September 4, 2025 was furnished with U.S. Bank Trust Company as trustee
  • Legal opinion and consent from Davis Polk & Wardwell LLP were included as exhibits
Negative
  • None.

Insights

TL;DR: The filing documents underwriting and indenture exhibits consistent with a securities transaction or debt issuance process.

The 8-K lists an underwriting agreement and a supplemental indenture, indicating The Cigna Group completed procedural documentation with underwriters and the trustee. The inclusion of a law firm opinion and consent is standard for registered offerings or debt instrument amendments. The filing itself contains exhibit references but does not disclose economic terms, sizes, or whether this relates to debt, equity, or shelf issuance; therefore material financial impact cannot be assessed from this content alone.

TL;DR: Required legal and trustee documents were furnished, reflecting compliance with disclosure and execution steps.

The exhibit list shows execution of transaction documentation and delivery of counsel opinion and consent, which are typical governance steps for registered transactions. The 8-K provides procedural transparency by identifying parties (underwriters, trustee, counsel) but omits transaction specifics such as securities type, amounts, or effective dates beyond exhibit dates, limiting assessment of governance or shareholder impact.

The Cigna Group ha depositato un modulo 8-K riportando l'inclusione di allegati relativi alla transazione datati 2 e 4 settembre 2025. La societ脿 ha allegato un Underwriting Agreement del 2 settembre 2025 tra The Cigna Group e BofA Securities, Citigroup, HSBC Securities (USA) e Morgan Stanley in qualit脿 di rappresentanti degli offerenti. 脠 stato incluso anche il Supplemental Indenture n. 8 datato 4 settembre 2025 con U.S. Bank Trust Company, National Association come trustee, un parere legale di Davis Polk & Wardwell LLP e il relativo consenso dello studio. Nel documento 猫 indicata la sede principale della societ脿 a Bloomfield, Connecticut e il simbolo di negoziazione CI alla NYSE.

The Cigna Group present贸 un formulario 8-K informando sobre la incorporaci贸n de anexos relacionados con la transacci贸n fechados el 2 y el 4 de septiembre de 2025. La compa帽铆a adjunt贸 un Underwriting Agreement con fecha 2 de septiembre de 2025 entre The Cigna Group y BofA Securities, Citigroup, HSBC Securities (USA) y Morgan Stanley como representantes de los suscriptores. Tambi茅n incluy贸 el Supplemental Indenture n.潞 8 fechado el 4 de septiembre de 2025 con U.S. Bank Trust Company, National Association como fideicomisario, un dictamen legal de Davis Polk & Wardwell LLP y el consentimiento de dicha firma. La presentaci贸n se帽ala la oficina ejecutiva principal en Bloomfield, Connecticut y el s铆mbolo de cotizaci贸n CI en la NYSE.

The Cigna Group電� 2025雲� 9鞗� 2鞚� 氚� 9鞗� 4鞚检瀽 瓯半灅 甏�霠� 靹滊鞚� 鞝滌稖鞚� 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 2025雲� 9鞗� 2鞚检瀽 Underwriting Agreement毳� The Cigna Group瓿� 鞚胳垬鞚� 雽�響滊靹� BofA Securities, Citigroup, HSBC Securities (USA), Morgan Stanley 臧勳棎 觳秬頄堨姷雼堧嫟. 霕愴暅 2025雲� 9鞗� 4鞚检瀽 Supplemental Indenture No. 8毳� 靾橅儊鞛愳澑 U.S. Bank Trust Company, National Association瓿� 頃粯 韽暔頄堨溂氅�, Davis Polk & Wardwell LLP鞚� 氩曥爜 鞚橁铂靹滌檧 攴� 須岇偓鞚� 霃欖潣靹滊弰 觳秬霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 氤胳偓鞚� 靻岇灛歆�臧� 旖旊劋韹办环欤� 敫旊８頃勲摐鞚措┌ NYSE 瓯半灅 鞁臣鞚� CI搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.

The Cigna Group a d茅pos茅 un formulaire 8-K signalant l'ajout de pi猫ces li茅es 脿 la transaction dat茅es des 2 et 4 septembre 2025. La soci茅t茅 a joint un Underwriting Agreement dat茅 du 2 septembre 2025 entre The Cigna Group et BofA Securities, Citigroup, HSBC Securities (USA) et Morgan Stanley en tant que repr茅sentants des souscripteurs. Elle a 茅galement inclus le Supplemental Indenture n掳 8 dat茅 du 4 septembre 2025 avec U.S. Bank Trust Company, National Association en qualit茅 de fiduciaire, un avis juridique de Davis Polk & Wardwell LLP ainsi que le consentement de ce cabinet. Le d茅p么t indique le si猫ge social 脿 Bloomfield, Connecticut et le symbole de cotation CI 脿 la NYSE.

The Cigna Group reichte ein Formular 8-K ein und berichtete 眉ber die Einreichung transaktionsbezogener Anlagen vom 2. und 4. September 2025. Das Unternehmen f眉gte ein Underwriting Agreement vom 2. September 2025 zwischen The Cigna Group und BofA Securities, Citigroup, HSBC Securities (USA) und Morgan Stanley als Vertreter der Zeichner bei. Ebenfalls beigef眉gt ist das Supplemental Indenture Nr. 8 vom 4. September 2025 mit der U.S. Bank Trust Company, National Association als Treuh盲nder, ein rechtliches Gutachten von Davis Polk & Wardwell LLP sowie die Zustimmung dieser Kanzlei. In der Einreichung wird der Hauptsitz in Bloomfield, Connecticut und das B枚rsensymbol CI an der NYSE angegeben.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 4, 2025

The Cigna Group
(Exact name of registrant as specified in its charter)

Delaware
001-38769
82-4991898
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:
(860) 226-6000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.01
CI
New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 1.01  Entry into a Material Definitive Agreement.

On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

The Company intends to use the proceeds (i) to repay $2.0 billion of loans outstanding under the Term Loan Agreement, dated as of August 5, 2025, among the Company, the guarantors from time to time party thereto, the banks from time to time party thereto and Bank of America, N.A., as administrative agent, the proceeds of which were used to fund a strategic investment in another company, and (ii) the remainder for general corporate purposes, which may include investments and repayment of indebtedness. Pending such use, the net proceeds may be invested temporarily in short-term, interest-bearing, investment-grade securities or similar assets.

The terms of the Notes are governed by an Indenture, dated as of September 17, 2018 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by Supplemental Indenture No. 8 to the Base Indenture, dated as of September 4, 2025 (“Supplemental Indenture No. 8”), between the Company and the Trustee. Supplemental Indenture No. 8 with respect to the Notes (including the forms of the Notes) is filed as Exhibit 4.1 hereto.

The 2030 Notes will bear interest at a rate of 4.500% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2030. The 2032 Notes will bear interest at a rate of 4.875% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2032. The 2036 Notes will bear interest at a rate of 5.250% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2036. The 2056 Notes will bear interest at a rate of 6.000% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2056.

At any time prior to August 15, 2030 in the case of the 2030 Notes, July 15, 2032 in the case of the 2032 Notes, October 15, 2035 in the case of the 2036 Notes and July 15, 2055 in the case of the 2056 Notes, the Company may redeem some or all of the 2030 Notes, 2032 Notes, 2036 Notes or 2056 Notes, respectively, by paying a “make-whole premium” plus accrued and unpaid interest, if any, to the redemption date. At any time on or after August 15, 2030 in the case of the 2030 Notes, July 15, 2032 in the case of the 2032 Notes, October 15, 2035 in the case of the 2036 Notes and July 15, 2055 in the case of the 2056 Notes, the Company may redeem some or all of the 2030 Notes, 2032 Notes, 2036 Notes or 2056 Notes, respectively, by paying a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest, if any, to the redemption date.

The Indenture contains customary events of default and certain covenants including with respect to the Company’s ability to incur certain indebtedness secured by liens on common stock of the Company’s designated subsidiaries or to engage in certain consolidation, merger and sale of asset transactions.

The foregoing description of Supplemental Indenture No. 8 and the Notes does not purport to be complete and is qualified in its entirety by reference to Supplemental Indenture No. 8 (including the forms of the Notes), which is filed as Exhibit 4.1 hereto, and is incorporated herein by reference.

Item 2.03  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 8.01  Other Events.

On September 2, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities (USA) Inc. and Morgan Stanley & Co. LLC, as representatives of the underwriters named in Schedule I thereto, with respect to the issuance and sale by the Company of the Notes.

The Underwriting Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties, and termination provisions.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated by reference herein.

A copy of the opinion of Davis Polk & Wardwell LLP, counsel to the Company, relating to the legality of the Notes is filed as Exhibit 5.1 hereto.

Item 9.01  Financial Statements and Exhibits.

(d)          Exhibits.
Exhibit No.
  

Description
1.1
  
Underwriting Agreement, dated as of September 2, 2025, by and among The Cigna Group and BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities (USA) Inc. and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein.
4.1
  
Supplemental Indenture No. 8, dated as of September 4, 2025, between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee.
5.1
  
Opinion of Davis Polk & Wardwell LLP.
23.1
  
Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1).
104
  
Cover Page Interactive Data File (formatted in Inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
THE CIGNA GROUP
     
Date:
September 4, 2025
  
By:
/s/ Ann M. Dennison
       
Name:
Ann M. Dennison
       
Title:
Executive Vice President and Chief Financial Officer

Source:

FAQ

What exhibits did The Cigna Group file in this 8-K (CI)?

The filing lists an Underwriting Agreement (Sept 2, 2025), Supplemental Indenture No. 8 (Sept 4, 2025), an opinion of Davis Polk & Wardwell LLP, and that firm's consent.

Does the 8-K disclose the financial terms or size of any offering for CI?

No; the document only lists exhibits and parties by name and date and does not state amounts, security types, or financial terms.

Who are the underwriters named in the Underwriting Agreement?

The underwriters named as representatives are BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities (USA) Inc., and Morgan Stanley & Co. LLC.

Who is the trustee named in the Supplemental Indenture?

The trustee is U.S. Bank Trust Company, National Association.

Does the filing indicate any change of address or former name for The Cigna Group?

No; the filing lists the principal executive office in Bloomfield, Connecticut and states 'Not Applicable' for former name or address changes.
Stock CI logo
Cigna Group

NYSE:CI

CI Rankings

#180 Ranked by Market Cap
#1568 Ranked by Dividends

CI Latest News

Sep 4, 2025
AM Best Assigns Issue Credit Ratings and Indicative Issue Credit Ratings to The Cigna Group
Sep 2, 2025
Evernorth Health Services Announces Investment in Shields Health Solutions
Aug 5, 2025
Skipping the Dentist? Not Anymore: Cigna Expands Access to Flexible Dental Payments, Driving Meaningful Increases in Preventive Care and Critical Procedures
Jul 31, 2025
The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook
Jul 22, 2025
The Cigna Group Declares Quarterly Dividend

CI Latest SEC Filings

Sep 3, 2025
[Form 4] The Cigna Group Insider Trading Activity
Sep 3, 2025
[Form 4] The Cigna Group Insider Trading Activity
Sep 2, 2025
[424B5] The Cigna Group Prospectus Supplement (Debt Securities)
Sep 2, 2025
[S-3ASR] The Cigna Group SEC Filing
Sep 2, 2025
[8-K] The Cigna Group Reports Material Event

CI Stock Data

81.15B
262.66M
1.59%
90.16%
0.92%
Healthcare Plans
Hospital & Medical Service Plans
United States
BLOOMFIELD